DS
CPRX icon

DRW Securities’s Catalyst Pharmaceutical CPRX Stock Holding History

DRW Securities’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$396K Buy
16,000
+762
+5% +$18.2K 0.01% 737
2025
Q4 		$356K Buy
+15,238
New +$339K 0.01% 595
2016
Q3 		– Sell
-237,200
Closed -$168K – 87
2016
Q2 		$168K Buy
+237,200
New +$191K 0.01% 67

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

DRW Securities's CPRX Position: Q1 2026 in Review

DRW Securities increased its Catalyst Pharmaceutical (CPRX) stake by 5% in Q1 2026, buying an estimated $18.2K and bringing the position to 16,000 shares worth $396K. The position accounts for 0.01% of the portfolio, ranked #737.

DRW Securities first reported a position in CPRX in Q2 2016 and has held it in 3 quarters since. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • DRW Securities held 16,000 shares of Catalyst Pharmaceutical worth $396K as of Q1 2026.
  • DRW Securities bought 762 Catalyst Pharmaceutical shares in Q1 2026, an estimated $18.2K.
  • Catalyst Pharmaceutical made up 0.01% of DRW Securities's portfolio in Q1 2026, its #737 holding.
  • DRW Securities first reported a position in Catalyst Pharmaceutical in Q2 2016 and has held it in 3 quarters since.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on DRW Securities's 13F filing for Q1 2026, filed 13 May 2026.